DeepMed Research

Exelixis

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1994-01-01

Employees: 1.3K

Market Cap: $7.3B

Website: http://www.exelixis.com

Introduction: Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

Clinical Trials

A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib

Phase 2

Completed

Conditions: Gastrointestinal Stromal Tumors
Gastrointestinal Neoplasms

Interventions: Drug: XL820

First Posted Date: 2007-12-11

Last Posted Date: 2013-06-07

Lead Sponsor: Exelixis

Target Recruit Count: 16

Registration Number: NCT00570635

Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies

Phase 1

Terminated

Conditions: Lymphoma
Cancer

Interventions: Drug: XL228

First Posted Date: 2007-09-10

Last Posted Date: 2015-08-21

Lead Sponsor: Exelixis

Target Recruit Count: 84

Registration Number: NCT00526838

Locations: 🇺🇸
University of Michigan Health System, Ann Arbor, Michigan, United States
🇺🇸
UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States

and more 1 locations

A Safety Study of XL019 in Adults With Myelofibrosis

Phase 1

Terminated

Conditions: Myeloproliferative Disorders
Myelofibrosis
Polycythemia Vera
Thrombocythemia, Essential

First Posted Date: 2007-08-29

Last Posted Date: 2011-04-05

Lead Sponsor: Exelixis

Target Recruit Count: 100

Registration Number: NCT00522574

Locations: 🇺🇸
UCSF - Division of Hematology/Oncology, San Francisco, California, United States
🇺🇸
Mt. Sinai School of Medicine, New York, New York, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

and more 2 locations

A Study of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Adults With Advanced Malignancies

Phase 1

Terminated

Conditions: Cancer
Lymphoma

Interventions: Drug: XL844
Drug: Gemcitabine

First Posted Date: 2007-05-21

Last Posted Date: 2015-08-21

Lead Sponsor: Exelixis

Target Recruit Count: 28

Registration Number: NCT00475917

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸
M.D. Anderson Cancer Center, Houston, Texas, United States

Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute Lymphocytic Leukemia

Phase 1

Terminated

Conditions: Chronic Myeloid Leukemia
Leukemia, Lymphoblastic, Acute, Philadelphia-Positive

Interventions: Drug: XL228

First Posted Date: 2007-04-20

Last Posted Date: 2015-08-21

Lead Sponsor: Exelixis

Target Recruit Count: 49

Registration Number: NCT00464113

Locations: 🇺🇸
UCLA School of Medicine, Los Angeles, California, United States
🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States

and more 3 locations

Study of XL418 in Adults With Solid Tumors

Phase 1

Suspended

Conditions: Solid Tumors
Cancer

First Posted Date: 2007-04-13

Last Posted Date: 2008-06-04

Lead Sponsor: Exelixis

Target Recruit Count: 63

Registration Number: NCT00460278

Locations: 🇺🇸
Wayne State University, Detroit, Michigan, United States
🇺🇸
South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States

Study of XL281 in Adults With Solid Tumors

Phase 1

Completed

Conditions: Cancer
Non-small-cell Lung Cancer
Colorectal Cancer
Papillary Thyroid Cancer
Melanoma

Interventions: Drug: XL281
Drug: famotidine

First Posted Date: 2007-03-26

Last Posted Date: 2011-10-13

Lead Sponsor: Exelixis

Target Recruit Count: 180

Registration Number: NCT00451880

Locations: 🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

and more 3 locations

Study of XL820 Given Orally Daily to Subjects With Solid Tumors

Phase 1

Completed

Conditions: Cancer

First Posted Date: 2006-07-11

Last Posted Date: 2008-08-18

Lead Sponsor: Exelixis

Target Recruit Count: 30

Registration Number: NCT00350831

Locations: 🇺🇸
The Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
Cancer Therapy and Research Center, San Antonio, Texas, United States

Safety Study of XL844 in Subjects With Chronic Lymphocytic Leukemia

Phase 1

Terminated

Conditions: Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

First Posted Date: 2005-10-07

Last Posted Date: 2008-06-04

Lead Sponsor: Exelixis

Registration Number: NCT00234481

Locations: 🇺🇸
UCSD Moores Cancer Center, San Diego, California, United States
🇺🇸
City of Hope National Cancer Center, Duarte, California, United States
🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies

Phase 1

Completed

Conditions: Lymphoma
Cancer
Thyroid Carcinoma

Interventions: Drug: XL184

First Posted Date: 2005-09-22

Last Posted Date: 2013-02-27

Lead Sponsor: Exelixis

Target Recruit Count: 85

Registration Number: NCT00215605

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy